Email updates

Keep up to date with the latest news and content from Breast Cancer Research and BioMed Central.

Highly Accessed Letter

RAD51C germline mutations in breast and ovarian cancer patients

Mohammad R Akbari1, Patricia Tonin23, William D Foulkes234, Parviz Ghadirian5, Marc Tischkowitz24 and Steven A Narod1*

Author Affiliations

1 Women's College Research Institute, University of Toronto, Toronto, Ontario M5G 1N8, Canada

2 Program in Cancer Genetics, Departments of Human Genetics, Medicine and Oncology, McGill University, Montreal, Quebec H2W 1S6, Canada

3 The Research Institute, McGill University Health Centre, Montreal, Quebec H3G 1A4, Canada

4 Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada

5 Epidemiology Research Unit Research Centre, CHUM- Hôtel-Dieu, University of Montreal, Montreal, Quebec H2W 1T7, Canada

For all author emails, please log on.

Breast Cancer Research 2010, 12:404  doi:10.1186/bcr2619


See related letter by Silvestri et al., http://breast-cancer-research.com/content/12/4/404

Published: 19 August 2010

First paragraph (this article has no abstract)

The two breast cancer genes BRCA1 and BRCA2 account for approximately one-half of cases of hereditary breast cancer, and other genes, such as BRIP1, PALB2, and P53, account for a small additional fraction [1]. Recently, it has been proposed that RAD51C is also a breast cancer susceptibility gene [2]. A bi-allelic mutation of RAD51C was originally found in a family from Pakistan with features of Fanconi anemia [3]. Because several genes in the Fanconi anemia gene family are also breast cancer susceptibility genes (including BRCA2 (FANCD1) [4], BRIP1 (FANCJ) [5] and PALB2 (FANCN) [6]), Meindl and colleagues hypothesised that RAD51C might be a breast cancer gene [2]. A germline mutation was seen in 6 of 480 (1.3%) breast/ovarian cancer families from Germany, which had previously been found to be negative for mutations in BRCA1 and BRCA2. In each of the six families, the putative mutation co-segregated with the relevant cancers [2]. Each family with a mutation contained at least one case each of breast and ovarian cancer.